Abstract: SA-PO0846
Clinical Characteristics and Treatment Patterns in Patients with IgAN in Chongqing, China: Retrospective Cross-Sectional Study Using Regional Health Data
Session Information
- Glomerular Management: Real-World Lessons and Emerging Therapies
November 08, 2025 | Location: Exhibit Hall, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Glomerular Diseases
- 1402 Glomerular Diseases: Clinical, Outcomes, and Therapeutics
Authors
- Ouyang, Nan, The First Affiliated Hospital of Chongqing Medical University Department of Nephrology, Chongqing, China
- Li, Yang, Zhongshan Hospital Fudan University, Shanghai, China
- Liao, Xiaohui, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China
- Shi, Yiqin, Zhongshan Hospital Fudan University, Shanghai, China
- Shen, Bingbing, Chongqing Emergency Medical Center, Chongqing, China
- Shen, Ziyan, Zhongshan Hospital Fudan University, Shanghai, China
- Jiang, Yingsong, Chongqing Hospital of University of Chinese Academy of Sciences, Chongqing, China
- Jin, Shi, Zhongshan Hospital Fudan University, Shanghai, China
- Tang, Yuewu, Chongqing University Three Gorges Hospital, Chongqing, China
- Zhou, Zulian, Chongqing University Qianjiang Hospital, Chongqing, China
- Cai, Zhiyue, Chongqing University Fuling Hospital, Chongqing, China
- Sun, Xieyi, Chongqing Rongchang District People's Hospital, Chongqing, China
- Liao, Yuanjiang, The Ninth People's Hospital of Chongqing, Chongqing, China
- Du, Xiaogang, The First Affiliated Hospital of Chongqing Medical University Department of Nephrology, Chongqing, China
- Ding, Xiaoqiang, Zhongshan Hospital Fudan University, Shanghai, China
Background
Immunoglobulin A nephropathy (IgAN) is one of the most common primary glomerulonephritis and remains a leading cause of chronic kidney disease and end-stage kidney disease（ESKD). This study investigated clinical characteristics and contemporary management approaches of IgAN patients in west China to inform evidence-based practice status.
Methods
We conducted a retrospective cross-sectional analysis using Chongqing Health & Medical Big Data Platform database, including adults (≥18 years) with kidney biopsy records and diagnosed as primary IgAN between January 2018 and December 2024.
Results
From 2,766 eligible patients (50.07% male), the cohort demonstrated a mean age of 40.8 years (median 38.0). Baseline renal function stratification revealed: CKD stage I (37.43%), II (32.45%), IIIa (12.45%), IIIb(9.05%),IV (6.47%), and V (2.16%) . The proportions of 24-hour proteinuria <0.5 g, 0.5-1.0 g, 1.0-3.5 g, and >3.5 g were 29.2%, 21.41%, 35.64%, and 13.75%, respectively. Histopathological evaluation of kidney biopsy specimens demonstrated the following pathological feature distribution according to Oxford classification: M1 lesions in 47.48% of cases, E1 in 13.43%, S1 in 51.83%, T1-2 in 16.09%, and C1-2 in 22.5% of patients. Initial treatment regimens within 30 days post-diagnosis included: no treatment (10.5%), supportive management only (38.8%), glucocorticoid-based therapy (36.2%), and immunosuppressive agents(14.6%).
Conclusion
Our findings reveal two critical gaps in IgAN management: 1) 70.8% of patients are at risk of progressive loss of kidney function (>0.5 g/24h) at diagnosis, and 2) 49.3% received no treatment or supportive management only. These data underscore the urgent need for standardized treatment protocols and early intervention strategies of IgAN.